Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAU | P00749 | 2/20 | 0.56 |
| ▸ | PLG | P00747 | 1/20 | 0.56 |
| ▸ | PLAT | P00750 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | ERN1 | O75460 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.36 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.36 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.36 |
| ▸ | CDK1 | P06493 | 1/20 | 0.36 |
| ▸ | PIM1 | P11309 | 1/20 | 0.36 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30497136 | 1.00 | PLAU (0.56) | PLAUPLGPLATCYP1A2CYP2C19 | |
| SCHEMBL30470394 | 0.84 | PLAU (0.56) | PLAUPLGPLATCYP1A2CYP2C19 | |
| SCHEMBL582273 | 0.84 | PLAU (0.56) | PLAUPLGPLATCYP1A2CYP2C19 | |
| SCHEMBL30204386 | 0.76 | CYP2A6 (0.53) | PLAUPLGPLATCYP1A2CYP2C19 | |
| SCHEMBL22729150 | 0.76 | PLAU (0.51) | PLAUPLGPLATCYP1A2CYP2C19 | |
| SCHEMBL29439792 | 0.76 | PLAU (0.56) | PLAUPLGPLATCYP1A2CYP2C19 | |
| SCHEMBL3735578 | 0.76 | CYP2A6 (0.44) | CYP1A2KDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL13307548 | 0.76 | CYP2A6 (0.53) | PLAUPLGPLATCYP1A2CYP2C19 | |
| SCHEMBL29024926 | 0.76 | CTDSP1 (0.50) | PLAUPLGPLATHTTKDM4E | |
| SCHEMBL29439750 | 0.76 | PLAU (0.51) | PLAUPLGPLATCYP1A2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 115 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260132132-A1 | 3A,4,5,6-TETRAHYDRO-1 H-PYRAZOLO[3,4-C]PYRIDIN-7(7AH)-ONE DERIVATIVES AS FACTOR XIIA INHIBITORS | KALVISTA PHARMACEUTICALS LTD (GB) | 2026-05-14 | — | — | US | disclosed |
| EP-4615838-A1 | SUBSTITUTED BI-AND TRICYCLIC HSET INHIBITORS | Merck Patent GmbH (DE) | 2025-09-17 | — | — | EP | disclosed |
| EP-4577537-A1 | SUBSTITUTED BICYCLES AS HSET INHIBITORS | Merck Patent GmbH (DE) | 2025-07-02 | — | — | EP | disclosed |
| CN-120091998-A | Substituted bicyclic rings as HSET inhibitors | 默克专利股份公司 | 2025-06-03 | — | — | CN | disclosed |
| CN-120077042-A | 3A,4,5, 6-tetrahydro-1H-pyrazolo [3,4-C ] pyridin-7 (7 AH) -one derivatives as factor XIIa inhibitors | 卡尔维斯塔制药有限公司 | 2025-05-30 | — | — | CN | disclosed |
| US-20250084074-A1 | SUBSTITUTED HETEROCYCLES AS HSET INHIBITORS | MERCK PATENT GMBH (DE) | 2025-03-13 | — | — | US | disclosed |
| CN-119421877-A | Substituted heterocyclic compounds as HSET inhibitors | 默克专利股份公司 | 2025-02-11 | — | — | CN | disclosed |
| CN-118812505-A | PI5P4K gamma inhibitor compound, pharmaceutical composition, and preparation method and application thereof | 贵州医科大学 | 2024-10-22 | — | — | CN | disclosed |
| US-12110294-B2 | CD73 compounds | GILEAD SCIENCES, INC. (US) | 2024-10-08 | — | — | US | disclosed |
| US-20240239752-A1 | BICYCLIC HETEROAROMATIC INHIBITORS OF KLK5 | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2024-07-18 | — | — | US | disclosed |
| US-20050004177-A1 | Combination of an allosteric inhibitor of matrix metalloproteinase-13 and a ligand to an alpha-2-delta receptor | WARNER-LAMBERT COMPANY LLC | 2005-01-06 | — | — | US | disclosed |
| EP-1453789-A2 | N,N'-SUBSTITUTED-1,3-DIAMINO-2-HYDROXYPROPANE DERIVATIVES | Elan Pharmaceuticals, Inc. (US) | 2004-09-08 | — | — | EP | disclosed |
| US-20040171881-A1 | N,N'-substituted-1,3-diamino-2-hydroxypropane derivatives | PHARMACIA & UPJOHN COMPANY | 2004-09-02 | — | — | US | disclosed |
| US-20040063673-A1 | Cyclic compounds containing zinc binding groups as matrix metalloproteinase inhibitors | JOHNSON ADAM RICHARD (US) | 2004-04-01 | — | — | US | disclosed |
| US-20040044000-A1 | Isoquinoline derivatives as matrix metalloproteinase inhibitors | BUNKER AMY MAE (US) | 2004-03-04 | — | — | US | disclosed |
| WO-2004014384-A2 | CYCLIC COMPOUNDS CONTAINING ZINC BINDING GROUPS AS MATRIX METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2004-02-19 | — | — | WO | disclosed |
| WO-2004014379-A1 | ISOQUINOLINE DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2004-02-19 | — | — | WO | disclosed |
| US-20040024210-A1 | New compounds | PROXIMAGEN NEUROSCIENCE PLC (GB) | 2004-02-05 | — | — | US | disclosed |
| WO-2004000828-A1 | NEW COMPOUNDS USEFUL FOR THE TREATMENT OF OBESITY, TYPE II DIABETES AND CNS DISORDERS | BIOVITRUM AB (SE) | 2003-12-31 | — | — | WO | disclosed |
| WO-2003040096-A2 | N, N'-SUBSTITUTED-1,3-DIAMINO-2-HYDROXYPROPANE DERIVATIVES | ELAN PHARMACEUTICALS, INC. (US) | 2003-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260132132-A1 | 3A,4,5,6-TETRAHYDRO-1 H-PYRAZOLO[3,4-C]PYRIDIN-7(7AH)-ONE DERIVATIVES AS FACTOR XIIA INHIBITORS | F11, F13B, F7 | PLAU 171/4885PLG 43/4885PLAT 52/4885 |
| US-20050004177-A1 | Combination of an allosteric inhibitor of matrix metalloproteinase-13 and a ligand to an alpha-2-delta receptor | MMP13, MMP10, MMP11 | PLAU 410/4885PLG 325/4885PLAT 172/4885 |
| US-20250084074-A1 | SUBSTITUTED HETEROCYCLES AS HSET INHIBITORS | VHL, CDKN1A, CCNI | PLAU 4489/4885PLG 4319/4885PLAT 2606/4885 |
| US-20240239752-A1 | BICYCLIC HETEROAROMATIC INHIBITORS OF KLK5 | KLK5, KLK1, KLKB1 | PLAU 982/4885PLG 401/4885PLAT 1055/4885 |
| US-20040024210-A1 | New compounds | SULT1E1, SULT2A1, SULT1A1 | PLAU 3890/4885PLG 1475/4885PLAT 4039/4885 |
| US-12110294-B2 | CD73 compounds | ENTPD5, ENTPD1, NT5E | PLAU 2527/4885PLG 3327/4885PLAT 1666/4885 |
| US-20040171881-A1 | N,N'-substituted-1,3-diamino-2-hydroxypropane derivatives | BACE1, BACE2, PSEN1 | PLAU 1549/4885PLG 1861/4885PLAT 1300/4885 |
| US-20040063673-A1 | Cyclic compounds containing zinc binding groups as matrix metalloproteinase inhibitors | MMP13, MMP1, MMP11 | PLAU 1789/4885PLG 1053/4885PLAT 2096/4885 |
| US-20040044000-A1 | Isoquinoline derivatives as matrix metalloproteinase inhibitors | MMP1, MMP13, MMP9 | PLAU 802/4885PLG 652/4885PLAT 585/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.